Edition:
United States

Citius Pharmaceuticals Inc (CTXR.OQ)

CTXR.OQ on NASDAQ Stock Exchange Capital Market

2.88USD
20 Apr 2018
Change (% chg)

$0.11 (+3.97%)
Prev Close
$2.77
Open
$2.83
Day's High
$2.88
Day's Low
$2.76
Volume
11,968
Avg. Vol
8,241
52-wk High
$5.46
52-wk Low
$0.34

Latest Key Developments (Source: Significant Developments)

Citius Reports Progress In Hemorroid Treatment Program
Tuesday, 6 Mar 2018 08:00am EST 

March 6 (Reuters) - Citius Pharmaceuticals Inc ::CITIUS REPORTS PROGRESS IN HEMORROID TREATMENT PROGRAM.CITIUS PHARMACEUTICALS - SELECTING HIGHER POTENCY CORTICOSTEROID IN ITS STEROID/ANESTHETIC TOPICAL FORMULATION PROGRAM FOR TREATMENT OF HEMORRHOIDS.CITIUS PHARMACEUTICALS INC - NEW FORMULATION, CITI-002, WILL COMBINE LIDOCAINE WITH HIGHER POTENCY CORTICOSTEROID.CITIUS PHARMACEUTICALS INC - HELD A TYPE C MEETING WITH FDA TO DISCUSS RESULTS OF PHASE 2A STUDY.CITIUS PHARMACEUTICALS - MEETING WITH FDA ALSO TO OBTAIN ITS VIEW ON PLANS TO SUPPORT POTENTIAL FORMULATION CHANGE FOR PLANNED PHASE 2B STUDY.CITIUS PHARMACEUTICALS INC - REQUESTED FDA'S FEEDBACK ON PHASE 2B STUDY DESIGN.CITIUS PHARMACEUTICALS - PRE-CLINICAL, CLINICAL DEVELOPMENT PROGRAMS FOR CITI-002 PLANNED TO BE SIMILAR TO THOSE OF CITI-001.  Full Article

Citius Announces $6 Mln Registered Direct Offering Priced At-The-Market
Monday, 18 Dec 2017 08:00am EST 

Dec 18 (Reuters) - Citius Pharmaceuticals Inc ::CITIUS ANNOUNCES $6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.CITIUS PHARMACEUTICALS - ENTERED AGREEMENTS WITH SEVERAL INSTITUTIONAL, ACCREDITED INVESTORS TO BUY 1.3 MILLION SHARES AT $4.6925/SHARE.  Full Article

Citius Pharmaceuticals Says On Nov 27, Board Appointed Jaime Bartushak As CFO And Principal Financial Officer Of Co
Friday, 1 Dec 2017 05:14pm EST 

Dec 1 (Reuters) - Citius Pharmaceuticals Inc ::CITIUS PHARMACEUTICALS INC - ‍ON NOV 27, , BOARD APPOINTED JAIME BARTUSHAK AS CFO AND PRINCIPAL FINANCIAL OFFICER OF COMPANY, EFFECTIVE NOV. 27, 2017​.  Full Article

Citius Pharmaceuticals files for mixed shelf offering of up to $50 mln - SEC filing‍​
Thursday, 9 Nov 2017 05:46pm EST 

Nov 9 (Reuters) - Citius Pharmaceuticals Inc :Citius Pharmaceuticals Inc - files for mixed shelf offering of up to $50 million - SEC filing‍​.  Full Article

Citius pharmaceuticals receives "fast track" designation by FDA for mino-lok™ investigational trial
Tuesday, 31 Oct 2017 08:00am EDT 

Oct 31 (Reuters) - Citius Pharmaceuticals Inc :Citius Pharmaceuticals, Inc. Receives "fast track" designation by FDA for mino-lok™ investigational trial.  Full Article

Citius Pharmaceuticals provides phase 3 update on Mino-Lok clinical trial following FDA meeting
Tuesday, 5 Sep 2017 07:00am EDT 

Sept 5 (Reuters) - Citius Pharmaceuticals Inc ::Citius Pharmaceuticals, Inc provides phase 3 update on Mino-Lok™ clinical trial following FDA meeting.Citius Pharmaceuticals, Inc. Provides phase 3 update on mino-lok™ clinical trial following FDA meeting.Citius Pharmaceuticals Inc - ‍citius is currently recruiting sites for a phase 3 trial of Mino-Lok in United States​.Citius Pharmaceuticals Inc - ‍received feedback from u. s. Food and drug administration regarding amendments to phase 3 study plan for Mino-Lok​.Citius pharmaceuticals inc - ‍following discussion with FDA, Citius amended phase 3 study design to remove saline and heparin placebo control arm​.Citius Pharmaceuticals Inc - ‍fda agreed that an open label, superiority design would address company's concerns and would be acceptable for Mino-Lok​.  Full Article

BRIEF-Citius Pharmaceuticals To Sell Up To 1.4 Mln Shares Of Co's Common Stock

* CITIUS PHARMACEUTICALS - TO SELL OR OTHER DISPOSITION FROM TIME TO TIME OF UP TO 1.4 MILLION SHARES OF CO'S COMMON STOCK Source : https://bit.ly/2JdehV7 Further company coverage: (Reuters.Briefs@thomsonreuters.com)